

## INFORMATION DISCLOSURE STATEMENT


FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: February 22, 2008

ATTY DOCKET NO.  
2006\_1488ASERIAL NO.  
10/591,827APPLICANT  
Masahiro YAMAUCHI et al.FILING DATE  
September 6, 2006

GROUP



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2004/0022938	2/2004	Kato et al.			
	AB						
	AC						
	AD						
	AE						
	AF						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	BA	98/58630	12/1998	WO				
	BB	98/51278	11/1998	WO				
	BC							
	BD							
	BE							

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	S. C. Semple et al., "Efficient Encapsulation of Antisense Oligonucleotides in Lipid Vesicles using Ionizable Aminolipids: Formation of Novel Small Multilamellar Vesicle Structures", <i>Biochemica et Biophysica Acta</i> , Vol. 1510, pp. 152-166, 2001.
	CB	J. R. Bertrand et al., "Comparison of Antisense Oligonucleotides and siRNAs in Cell Culture and <i>In Vivo</i> ", <i>Biochemical and Biophysical Research Communications</i> , Vol. 296, pp. 1000-1004, 2002.
	CC	D. C. Litzinger et al., "Fate of Cationic Liposomes and their Complex with Oligonucleotide <i>In Vivo</i> ", <i>Biochimica et Biophysica Acta</i> , Vol. 1281, pp. 139-149, 1996.
	CD	C. F. Bennett et al., "Pharmacokinetics in Mice of a [ <sup>3</sup> H]-labeled Phosphorothioate Oligonucleotide Formulated in the Presence and Absence of a Cationic Lipid", <i>Journal of Controlled Release</i> , Vol. 41, pp. 121-130, 1996.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.